Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC)

被引：0
|
作者：
Zhang, Tian
Staats, Janet S.
Chan, Cliburn
Harrison, Michael Roger
O'Donnell, Peter H.
Batich, Kristen A.
Chen, Tianling
Krejsa, Cecile
Izumi, Raquel
George, Daniel J.
Weinhold, Kent J.
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
[2] Duke Univ, Duke Canc Inst, Med Ctr, Durham, NC USA
[3] Univ Chicago, Comprehens Canc Ctr, Chicago, IL 60637 USA
[4] ICON Dev Soult, Palo Alto, CA USA
[5] Acerta Pharma, Redwood City, CA USA
[6] Duke Univ, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4533
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4533
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Combined checkpoint immunotherapy and cytotoxic chemotherapy: Further results from a phase Ib/II trial of pembrolizumab and docetaxel or gemcitabine in patients with advanced or metastatic urothelial cancer
    Parikh, Mamta
    Pan, Chong-xian
    Beckett, Laurel
    Li, Yueju
    Robles, Daniel
    DeVisser, Christina
    Lara, Primo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] A phase Ib/II study of cetuximab and pembrolizumab in metastatic colorectal cancer
    Fountzilas, C.
    Mukherjee, S.
    Saltzman, J.
    Bajor, D.
    Muhitch, J.
    Abrams, S.
    Maguire, O.
    Minderman, H.
    Wang, K.
    Hutson, A.
    Hicks, K.
    Ventola, J.
    Kalinski, P.
    Iyer, R.
    Boland, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S140 - S140
  • [43] Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer
    Yuan, Yuan
    Lee, Jin Sun
    Yost, Susan E.
    Frankel, Paul H.
    Ruel, Christopher
    Egelston, Colt A.
    Guo, Weihua
    Padam, Simran
    Tang, Aileen
    Martinez, Norma
    Schmolze, Daniel
    Presant, Cary
    Ebrahimi, Behnam
    Yeon, Christina
    Sedrak, Mina
    Patel, Niki
    Portnow, Jana
    Lee, Peter
    Mortimer, Joanne
    EUROPEAN JOURNAL OF CANCER, 2021, 154 : 11 - 20
  • [44] Immunogenicity of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple negative breast cancer
    Egelston, Colt A.
    Guo, Weihua
    Yost, Susan E.
    Ge, Xuan
    Lee, Jin Sun
    Frankel, Paul H.
    Cui, Yujie
    Ruel, Christopher
    Schmolze, Daniel
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Karimi, Misagh
    Somlo, George
    Lee, Peter
    Waisman, James
    Yuan, Yuan
    CANCER RESEARCH, 2023, 83 (05)
  • [45] Preexisting Autoantibodies and Immune Related Adverse Events in Metastatic Urothelial Carcinoma Patients Treated by Pembrolizumab
    Castel-Ajgal, Zahra
    Goulvestre, Claire
    Zaibet, Sonia
    Arrondeau, Jennifer
    Bretagne, Marie
    Peyromaure, Michael
    Batteux, Frederic
    Alexandre, Jerome
    Goldwasser, Francois
    Huillard, Olivier
    CLINICAL GENITOURINARY CANCER, 2022, 20 (05) : E362 - E368
  • [46] Phase Ib trial of olinvacimab and pembrolizumab in patients with metastatic triple-negative breast cancer
    Chan, Arlene
    Moylan, Eugene
    Jackson, Sally
    Devoto, Jeannette
    Jones, Nicola
    Radmil, Silvie
    Wilkinson, Kate
    Roohullah, Aflah
    Adam, Tamiem
    Lee, Seon Young
    Lee, Weon Sup
    Yoo, Jin-San
    CANCER RESEARCH, 2021, 81 (04)
  • [47] Multicenter phase II trial of pembrolizumab (pembro) in previously-treated metastatic esophageal cancer.
    Enzinger, Peter C.
    McCleary, Nadine Jackson
    Horick, Nora
    Cleary, James M.
    Rubinson, Douglas Adam
    Fitzpatrick, Bridget
    Graham, Christopher
    Clark, Jeffrey W.
    Patel, Anuj K.
    Pectasides, Eirini
    Perez, Kimberly
    Yurgelun, Matthew B.
    Azzoli, Christopher G.
    Enzinger, Andrea Catherine
    Gainor, Justin F.
    Schlechter, Benjamin L.
    Meyerhardt, Jeffrey A.
    Ng, Kimmie
    Bass, Adam Joel
    Fuchs, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] Combination checkpoint immunotherapy and cytotoxic chemotherapy: Further results from a phase Ib/II trial of pembrolizumab and docetaxel or gemcitabine in patients with advanced or metastatic urothelial cancer.
    Parikh, Mamta
    Pan, Chong-Xian
    Beckett, Laurel
    Li, Yueju
    Robles, Daniel
    DeVisser, Christina
    Lara, Primo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [49] Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial
    Nishiyama, Hiroyuki
    Yamamoto, Yoshiaki
    Sassa, Naoto
    Nishimura, Kazuo
    Fujimoto, Kiyohide
    Fukasawa, Satoshi
    Yokoyama, Minato
    Enokida, Hideki
    Takahashi, Kenichi
    Tanaka, Yoshinobu
    Imai, Kentaro
    Shimamoto, Takashi
    Perini, Rodolfo
    Frenkl, Tara
    Bajorin, Dean
    Bellmunt, Joaquim
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (01) : 165 - 174
  • [50] Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial
    Hiroyuki Nishiyama
    Yoshiaki Yamamoto
    Naoto Sassa
    Kazuo Nishimura
    Kiyohide Fujimoto
    Satoshi Fukasawa
    Minato Yokoyama
    Hideki Enokida
    Kenichi Takahashi
    Yoshinobu Tanaka
    Kentaro Imai
    Takashi Shimamoto
    Rodolfo Perini
    Tara Frenkl
    Dean Bajorin
    Joaquim Bellmunt
    International Journal of Clinical Oncology, 2020, 25 : 165 - 174
12345